Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 5/20 | 0.49 |
| ▸ | METAP1 | P53582 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4267098 | 0.88 | METAP2 (0.51) | METAP2METAP1NPC1RAB9AHDAC3 | |
| Cystine SCHEMBL9132888 | 0.87 | METAP2 (0.47) | METAP2METAP1NPC1RAB9AHDAC3 | |
| Bromide SCHEMBL4657453 | 0.85 | HDAC3 (0.48) | METAP2METAP1NPC1RAB9AHDAC3 | |
| SCHEMBL7043430 | 0.82 | METAP2 (0.46) | METAP2METAP1NPC1RAB9AHDAC3 | |
| SCHEMBL985997 | 0.82 | LARS1 (0.58) | METAP2METAP1NPC1RAB9AHDAC3 | |
| SCHEMBL7700177 | 0.81 | ALDH1A1 (0.50) | NPC1RAB9AHDAC3HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL8669233 | 0.81 | LARS1 (0.57) | METAP2METAP1NPC1RAB9AHDAC3 | |
| SCHEMBL10635436 | 0.78 | FURIN (0.45) | KMT2A | |
| SCHEMBL11010750 | 0.78 | PKM (0.45) | MEN1KMT2A | |
| SCHEMBL9390095 | 0.77 | METAP2 (0.49) | METAP2NPC1RAB9AHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3206723-A1 | BIOLOGICAL INDICATOR | American Sterilizer Company (US) | 2017-08-23 | — | — | EP | claimed |
| US-9701968-B2 | Biological indicator | AMERICAN STERILIZER COMPANY (US) | 2017-07-11 | — | — | US | claimed |
| US-20160312263-A1 | BIOLOGICAL INDICATOR | AMERICAN STERILIZER CO (US) | 2016-10-27 | — | — | US | claimed |
| WO-2016060714-A1 | BIOLOGICAL INDICATOR | AMERICAN STERILIZER COMPANY (US) | 2016-04-21 | — | — | WO | claimed |
| US-20160102335-A1 | BIOLOGICAL INDICATOR | AMERICAN STERILIZER COMPANY | 2016-04-14 | — | — | US | claimed |
| US-8507248-B2 | Genetically engineered biological indicator | AMERICAN STERILIZER COMPANY (US) | 2013-08-13 | — | — | US | claimed |
| US-8173389-B2 | Process for determining the effectiveness of a sterilization | AMERICAN STERILIZER COMPANY (US) | 2012-05-08 | — | — | US | claimed |
| US-20100267044-A1 | GENETICALLY ENGINEERED BIOLOGICAL INDICATOR | FRANCISKOVICH PHILLIP P | 2010-10-21 | — | — | US | claimed |
| EP-2084294-A2 | STERILIZATION INDICATOR | American Sterilizer Company (US) | 2009-08-05 | — | — | EP | claimed |
| EP-2084293-A2 | GENETICALLY ENGINEERED BIOLOGICAL INDICATOR | American Sterilizer Company (US) | 2009-08-05 | — | — | EP | claimed |
| US-20090117603-A1 | STERILIZATION INDICATOR | FRANCISKOVICH PHILLIP P | 2009-05-07 | — | — | US | claimed |
| WO-2008082728-A2 | STERILIZATION INDICATOR | AMERICAN STERILIZER COMPANY (US) | 2008-07-10 | — | — | WO | claimed |
| WO-2008079469-A2 | GENETICALLY ENGINEERED BIOLOGICAL INDICATOR | AMERICAN STERILIZER COMPANY (US) | 2008-07-03 | — | — | WO | claimed |
| US-20080070231-A1 | Reporter genes taken up by microorganism, and repressor gene inhibits expression | AMERICAN STERILIZER COMPANY | 2008-03-20 | — | — | US | claimed |
| US-20080070272-A1 | STERILIZATION INDICATOR | AMERICAN STERILIZER COMPANY | 2008-03-20 | — | — | US | claimed |
| US-6623955-B2 | Exposing source of active enzyme to sterilization cycle, contacting enzyme after cycle with aqueous buffer and substrate specific for and reactive with active enzyme to form enzyme modified product, detecting viable microorganisms | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-23 | — | — | US | claimed |
| US-20260137736-A1 | PROBIOTIC LACTOBACILLUS STRAIN COMPOSITIONS AND APPLICATIONS THEREFOR INCLUDING FOR LEAKY GUT AND INFLAMMATION | BIOMEDIT LLC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12564613-B2 | Strains having effects of preventing or treating cancers | GENOME AND COMPANY (KR) | 2026-03-03 | — | — | US | disclosed |
| EP-0361977-A2 | Peptides having T cell suppressor activity | IMMUNOBIOLOGY RESEARCH INSTITUTE, INC. (US) | 1990-04-04 | — | — | EP | disclosed |
| CN-87103752-A | Prepare a kind of monadic method for compositions that suppresses or eliminate | — | 1988-09-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137736-A1 | PROBIOTIC LACTOBACILLUS STRAIN COMPOSITIONS AND APPLICATIONS THEREFOR INCLUDING FOR LEAKY GUT AND INFLAMMATION | FABP2, SLC10A2, ALPI | METAP2 1827/4885METAP1 1314/4885NPC1 2028/4885 |
| US-12564613-B2 | Strains having effects of preventing or treating cancers | PDCD1, TOP1, CD274 | METAP2 4215/4885METAP1 2212/4885NPC1 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.